Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro

被引:24
作者
Adam, Albert [1 ]
Montpas, Nicolas [1 ]
Keire, David [2 ]
Desormeaux, Anik [1 ]
Brown, Nancy J. [3 ]
Marceau, Francois [4 ]
Westenberger, Benjamin [2 ]
机构
[1] Univ Montreal, Fac Pharm, Montreal, PQ H3T 1J4, Canada
[2] US FDA, Div Pharmaceut Anal, St Louis, MO 63101 USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA
[4] CHUL CHUQ, Rheumathol & Immunol Res Ctr, Quebec City, PQ G1V 4G2, Canada
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
Heparin; Oversulfated chondroitin sulfate; Bradykinin; Anaphylactoid reaction; TISSUE-PLASMINOGEN ACTIVATOR; ADVERSE CLINICAL EVENTS; ANAPHYLACTOID REACTIONS; PHARMACOLOGICAL PROFILE; DEXTRAN SULFATE; CONTACT SYSTEM; HUMAN-PLASMA; HEMODIALYSIS; INHIBITORS; ACE;
D O I
10.1016/j.biomaterials.2010.03.074
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Oversulfated chondroitin sulfate (OSCS) contaminated heparin has been associated with severe anaphylactoid reaction (AR), mainly in dialysed patients. Although attributed to bradykinin (BK) released during contact system activation by OSCS, no definitive evidence exists until now for a BK release during incubation of contaminated heparin with human plasma. In this study, we investigated the kinin forming capacity of OSCS and OSCS contaminated heparin when incubated in vitro with a pool of human plasma. At 100 mu g/mL, OSCS liberates BK in a profile similar but not identical to dextran sulfate, a well known activator of the plasma contact system. The results have highlighted that the quantity of BK accumulated during contact system activation depends not only on the concentration of OSCS but also on the plasma dilution and the presence of an angiotensin converting enzyme inhibitor. We demonstrate a highly significant correlation between the concentration of OSCS present in the contaminated heparin and BK released concentration. In conclusion, for the first time, we show that OSCS contaminated heparin incubated with human plasma has the capacity to liberate BK at a concentration that could explain the role of this inflammatory peptide in the pathophysiology of AR associated with OSCS contaminated heparin. Disclaimer: The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5741 / 5748
页数:8
相关论文
共 38 条
  • [1] ADAM A, 1985, CLIN CHEM, V31, P1533
  • [2] ADAM A, 1985, J CLIN CHEM CLIN BIO, V23, P203
  • [3] Acute adverse effects of angiotensin-converting-enzyme inhibitors
    Adam, Albert
    Desormeaux, Anik
    Moreau, Marie-Eve
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2007, 191 (07): : 1433 - 1443
  • [4] Bachvarov DR, 2001, J PHARMACOL EXP THER, V297, P19
  • [5] Guidelines on the use and monitoring of heparin
    Baglin, T
    Barrowcliffe, TW
    Cohen, A
    Greaves, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (01) : 19 - 34
  • [6] B-9972 (D-Arg-[Hyp3, IgI5, Oic7, IgI8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3, IgI5, D-IgI7, Oic8]-bradykinin):: Pharmacologic profile and effective induction of receptor degradation
    Bawolak, Marie-Therese
    Gera, Lajos
    Morissette, Guillaume
    Stewart, John M.
    Marceau, Francois
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (02) : 534 - 546
  • [7] Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis:: role of serum ACE and aminopeptidase P
    Blais, C
    Marc-Aurèle, J
    Simmons, WH
    Loute, G
    Thibault, P
    Skidgel, RA
    Adam, A
    [J]. PEPTIDES, 1999, 20 (04) : 421 - 430
  • [8] Outbreak of Adverse Reactions Associated with Contaminated Heparin
    Blossom, David B.
    Kallen, Alexander J.
    Patel, Priti R.
    Elward, Alexis
    Robinson, Luke
    Gao, Ganpan
    Langer, Robert
    Perkins, Kiran M.
    Jaeger, Jennifer L.
    Kurkjian, Katie M.
    Jones, Marilyn
    Schillie, Sarah F.
    Shehab, Nadine
    Ketterer, Daniel
    Venkataraman, Ganesh
    Kishimoto, Takashi Kei
    Shriver, Zachary
    McMahon, Ann W.
    Austen, K. Frank
    Kozlowski, Steven
    Srinivasan, Arjun
    Turabelidze, George
    Gould, Carolyn V.
    Arduino, Matthew J.
    Sasisekharan, Ram
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (25) : 2674 - 2684
  • [9] Effect of oversulfation on the chemical and biological properties of chondroitin-4-sulfate
    Carranza, Yaneth E.
    Durand-Rougley, Clarissa
    Doctor, Vasant
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (06) : 483 - 487
  • [10] Effect of oversulfated chondroitin-6-sulfate or oversulfated fucoidan in the activation of glutamic plasminogen by tissue plasminogen activator: role of lysine and cyanogen bromide-fibrinogen
    Carranza, Yaneth E.
    Anderson, Dorian
    Doctor, Vasant
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (01) : 60 - 65